

Thrombus aspiration in STEMI: Routine or selective?

Gregg W. Stone MD

*Columbia University Medical Center
Cardiovascular Research Foundation*



CARDIOVASCULAR RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER

Impact of Macroscopic Distal Emboli


**DE occurred
in 27 of 178
(15%) pts after
primary PTCA**



↓ **ST res**

↑ **Infarct size**


↑ **Mortality**



Mechanical Approaches to Thrombus


Thrombus aspiration

(Rinspirator, Pronto, Export, Rescue, Diver CE, etc.)




Thrombectomy

(AngioJet, X-Sizer)




Distal protection (GuardWire, FilterWire, AngioGuard, etc.)




Distal Protection and Thrombectomy in AMI

**Macroscopic embolic debris can be
retrieved from >75% of cases**




TAPAS: 1,071 pts with STEMI undergoing PCI randomized in the ER to aspiration (Export) vs. control


Myocardial Blush (1° EP)



ST-segment Resolution





TAPAS: 1,071 pts with STEMI undergoing primary PCI randomized in the ER to manual aspiration (Export) vs. control



Aspiration Trials to Decrease Infarct Size

Have been mostly met with frustration

The concept of reducing embolic load




Embololic Protection During Primary PCI: Impact of single vs. multicenter studies


25 RCTs, 5919 pts

2460 pts in single center trials, 3459 pts in multicenter trials

Predictors of ST resolution



Predictors of mortality



INFUSE-AMI Trial

452 pts with anterior STEMI

Anticipated Sx to PCI <5 hrs, TIMI 0-2 flow in prox or mid LAD

Primary PCI with bivalirudin anticoagulation

Pre-loaded with aspirin and
clopidogrel 600 mg or prasugrel 60 mg

Stratified by symptoms to angio <3 vs ≥3 hrs,
and prox vs mid LAD occlusion

R
1:1

Manual aspiration

No aspiration

R
1:1

IC Abcx

No Abcx

R
1:1

IC Abcx

No Abcx

Primary endpoint: Infarct size at 30 days (cMRI)

2° endpoints: TIMI flow, blush, ST-resolution, MACE (30d, 1 yr)

INFUSE-AMI

**Manual aspiration
vs.
no aspiration**

Pooled across the abciximab randomization

INFUSE-AMI: Baseline characteristics

	Manual aspiration N=229	No aspiration N=223
Age (years)	61 [53, 70]	60 [51, 69]
Male	73.8%	74.0%
Hypertension	33.2%	29.6%
Hyperlipidemia	16.7%	14.8%
Diabetes mellitus	14.9%	7.6%
Cig. smoking, current	43.4%	48.9%
Prior MI	0.4%	1.4%
Prior PCI	2.2%	2.3%
Killip class II-IV	20.6%	16.6%
Sx - hosp arrival, mins	98 [65, 152]	100 [70, 145]
Infarct artery		
- Proximal LAD	64.6%	66.8%
- Mid LAD	35.4%	33.2%
LVEF, % (site)	40 [35, 50]	40 [35, 50]

INFUSE-AMI: Meds and procedures


	Manual aspiration N=229	No aspiration N=223	P value
TIMI flow pre-PCI 0/1*	73.4%	70.0%	0.42
Blush pre-PCI 0/1*	85.5%	82.4%	0.37
Hospital - 1 st device, mins	43 [30, 63]	48 [35, 70]	0.02
Aspiration performed	98.3%**	4.0%	<0.001
Abciximab administered	50.7%	50.2%	0.93
N lesions treated	1.1 ± 0.4	1.1 ± 0.4	0.46
DES implanted	74.2%	70.9%	0.42
Stent length (mm)	24 [18, 32]	24 [18, 35]	0.30
Max stent diameter (mm)	3.0 [3.0, 3.5]	3.0 [3.0, 3.5]	0.20

*Core laboratory assessed; **6F Export used in all but 3 cases, with thrombus retrieved in 78.9%

INFUSE-AMI: Reperfusion post-PCI*


Manual aspiration

N=229



No aspiration

N=223



P=0.36



Corrected TIMI
frame counts:

20 [16, 26]

vs.

20 [16, 26]


P=0.40



P=0.26

*Core laboratory assessed


INFUSE-AMI: STR 60 minutes post-PCI*



*Core laboratory assessed

INFUSE-AMI: Infarct size at 30 days*

- Primary endpoint -



*Core laboratory assessed. No interaction was present between the 2 randomization groups for the primary 30-day infarct size endpoint (p=0.46)

INFUSE-AMI: cMRI at 30 days*

	Manual aspiration N=186	No aspiration N=186	P value
Total LV mass, grams	128.3 [108.9, 149.8]	132.0 [107.6, 156.1]	0.50
Infarct mass, grams	20.3 [9.7, 31.7]	21.0 [9.1, 34.1]	0.36
Infarct mass (% of total LV mass)	17.0 [9.0, 22.8]	17.3 [7.1, 25.5]	0.51
Total abnormal wall motion score	7.5 [2.0, 10.0]	7.5 [2.0, 10.0]	0.89
LVEF (%)	49.6 [43.3, 56.8]	49.5 [41.8, 57.6]	0.66

*Core laboratory assessed

INFUSE-AMI: 30-day clinical efficacy


	Manual aspiration N=229	No aspiration N=223	P value
Death	3.1% (7)	2.7% (6)	0.81
Reinfarction	0.5% (1)	0.9% (2)	0.55
New onset severe HF	3.5% (8)	4.1% (9)	0.77
Rehospitalization for HF	0.0% (0)	0.9% (2)	0.15
Stroke	0.0% (0)	0.5% (1)	0.31
Clinically-driven TVR	0.5% (1)	1.8% (4)	0.17
Stent thrombosis, def/prob*	1.4% (3)	0.5% (1)	0.33
MACCE	3.1% (7)	5.0% (11)	0.31
MACE	6.6% (15)	7.2% (16)	0.81

Data are Kaplan-Meier estimates (n of events). *No cases of acute (<24 hr) stent thrombosis occurred. MACE = death, reinfarction, new onset severe heart failure (HF) or rehospitalization for HF; MACCE = death, reinfarction, stroke or clinically-driven TVR

55 yo man with crushing chest pain

Symptoms to ER 78 minutes

Baseline ECG



55 yo man with crushing chest pain

Symptoms to ER 78 minutes

Baseline LV gram




**Anterior,
apical
akinesis**

**LVEF
33%**

55 yo man with crushing chest pain

Symptoms to ER 78 minutes

Baseline LCA




55 yo man with crushing chest pain

Symptoms to ER 78 minutes


Aspiration with the Export

ER to device
45 mins



55 yo man with crushing chest pain
Symptoms to ER 78 min; ER to device 45 min

Post aspiration



TIMI 2
flow
MBG 0

55 yo man with crushing chest pain
Symptoms to ER 78 min; ER to device 45 min

**Bolus abciximab infusion through the
Clearway Rx**



55 yo man with crushing chest pain
Symptoms to ER 78 min; ER to device 45 min


Post IC abciximab



TIMI 3
flow
cTFC 32
MBG 2


55 yo man with crushing chest pain
Symptoms to ER 78 min; ER to device 45 min

Final post stent




TIMI 3
flow
cTFC 17
MBG 3

55 yo man with crushing chest pain
Symptoms to ER 78 min; ER to device 45 min
60' Post-PCI ECG



ST-segment resolution 92%


55 yo man with crushing chest pain:
Symptoms to ER 78 min; ER to device 45 min
30-day cMRI



Total myocardial mass = 79.9 g; infarct size = 27.6 g;

Isz = 34.6% of LV

**55 yo man with crushing chest pain:
Symptoms to ER 78 min; ER to device 45 min**



30-day cMRI

LVEDV = 147.2 ml;
LVESV = 72.1 ml;

LVEF 51.0%

**Anterior, apical
and septal
akinesis**

INFUSE-AMI: Conclusions & Implications

In patients presenting early in the course of a large evolving anterior STEMI undergoing primary PCI with bivalirudin anticoagulation:

Manual aspiration with the 6F Export Catheter did not reduce infarct size

- The final word on aspiration in STEMI awaits the ongoing large-scale randomized TOTAL and TASTE trials
- Until this time, aspiration in STEMI should be used selectively, in cases of massive thrombus after wire passage, or refractory thrombus after PCI